Medinova Diagnostic Services Ltd

Medinova Diagnostic Services reported a decline in Q2 FY26 net sales and profit, indicating ongoing revenue volatility and financial challenges, including a negative book value. While operating margins improved year-on-year, concerns about stability and profitability persist.

Medinova Diagno has experienced fluctuations in financial performance, with net sales declining from 13.20 Cr in March 2022 to 9.81 Cr in March 2025, while profit before tax increased slightly from 2.28 Cr to 2.50 Cr in the same period. Despite challenges, cash flow from operating activities remained stable at 2.00 Cr.

As of 03-Nov, Medinova Diagnostic Services Ltd is seeing a price increase to Rs 41.64, up 5.47%, and has outperformed its sector today. However, a significant drop in investor participation raises concerns about the sustainability of this upward trend.

Medinova Diagnostic Services' latest results for Q3 2025 show a decline, with net sales down 8.09% and net profit reduced by 22.73%, indicating a slowdown in growth and efficiency compared to the previous quarter.

Medinova Diagno's historical performance shows declining net sales from 13.20 Cr in Mar'22 to 9.81 Cr in Mar'25, while operating profit improved from 1.20 Cr in Mar'20 to 2.99 Cr in Mar'25. Total assets and liabilities increased from 3.80 Cr in Mar'20 to 6.57 Cr in Mar'25, with stable cash flow from operations at 2.00 Cr from Mar'24 to Mar'25.

As of 10-Oct, Medinova Diagnostic Services Ltd is priced at 39.00, showing a slight increase but overall trading below key moving averages, indicating a bearish trend. Despite a recent uptick, the stock has declined significantly over the past week and month, coupled with weak fundamentals and reduced investor participation, suggesting it may be viewed as risky.

Medinova Diagno has experienced a decline in net sales from 13.20 Cr in Mar'22 to 9.81 Cr in Mar'25, with profit after tax decreasing to 1.90 Cr in Mar'25. Despite these challenges, operating profit improved, and total assets and liabilities increased during the same period.

As of 01-October, Medinova Diagnostic Services Ltd's stock price is Rs 41.38, up 2.99%, with a recent 6.02% gain over three days, outperforming its sector. However, the company has a negative book value and weak fundamentals, raising concerns about its long-term viability despite short-term gains.

Medinova Diagno's historical performance shows fluctuating net sales, declining from 13.20 Cr in Mar'22 to 9.81 Cr in Mar'25, with a slight recovery in Mar'23. Despite this, operating profit improved to 2.99 Cr in Mar'25, and total assets increased to 6.57 Cr, indicating stable cash flow and consistent operational performance.

As of 26-Sep, Medinova Diagnostic Services Ltd's stock price is Rs 38.60, reflecting a 3.36% decline and a bearish trend as it trades below all major moving averages. Despite a positive long-term performance, the company faces challenges such as high debt and weak fundamentals, leading to underperformance compared to the market.

Medinova Diagno has seen a decline in net sales from INR 13.20 crore in March 2022 to INR 9.81 crore in March 2025, despite improved cost management and stable cash flow. While total assets increased, total liabilities also rose, indicating a consistent debt level.

As of 19-Sep, Medinova Diagnostic Services Ltd is experiencing a price increase to 41.40, with a year-to-date return of 11.14% and a 3-year return of 59.85%. However, the company faces risks due to a negative book value, high debt levels, and a high PEG ratio of 6.7, leading to a mixed outlook for investors.